Asgard Therapeutics was awarded with Sweden’s SWElife innovation grant to support the project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration with Dr. Lennart Greiff from the Department of Otorhinolaryngology, Head & Neck Surgery, Skåne University Hospital (Lund) and Professor Malin Lindstedt from the Department of Immunotechnology at Lund University. The purpose of this project is to perform preclinical validation and clinical trial design of TrojanDC for Head & Neck cancer treatment.

Swelife is a strategic innovation programe, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programe’s partners. Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.